PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91018F00077Cell-based immunotherapy products — Leidos Biomedical Research, Inc

Leidos Biomedical Research, Inc holds $2.1B across 186 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent HHSN261201500003I. Recompete timing centers on the Aug 29, 2029 PoP end — agencies typically plan 12–18 months ahead.

Nih Nci

Awarding office

Leidos Biomedical Research, Inc

Recipient

Aug 29, 2029

PoP end

$20.2M

Obligated

$53.5M

Potential

561210

NAICS

M1HA

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Leidos Biomedical Research, Inc — $90

Contract facts

Federal

Contract number75N91018F00077

Also listed asHHSN261201500003I-75N91018F00077

AgencyNih Nci

Awarding officeNih Nci

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentLeidos Biomedical Research, Inc

CAGE3LYK6

UEIHV8BH9BPG8Y9

NAICS561210

No full NAICS 561210 intel page yet. Browse NAICS intelligence

PSCM1HA

Parent IDIQ / IDVHHSN261201500003I

Place of performanceFREDERICK MD

Pricing typeCost Plus Fixed Fee

Extent competedNot Competed

Related solicitationN01CO5240180

PoP startSep 24, 2018

PoP end (current)Aug 29, 2029

Obligated$20.2M

Current value$53.5M

Potential value$53.5M

CELL-BASED IMMUNOTHERAPY PRODUCTS is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $53.5M ($20.2M obligated). Current period of performance ends Aug 29, 2029. Place of performance: FREDERICK MD. Related solicitation N01CO5240180.

Recompete timing

Public

● Expiring in 1104 days

Current PoP ends Aug 29, 2029 (1104 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Feb 29, 2028.

Incumbent footprint

Public record

Leidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$2.1B · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

75N91021F00013

ENABLING NCI CLINICAL & RESEARCH DATA SHARING

$81.1M

Aug 31, 2026

75N91021F00006

FY21 CONSOLIDATED FACILITIES TASK ORDER C

$18.6M

Sep 4, 2026

75N91021F00017

ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

$12.1M

Sep 15, 2026

75N91021F00016

DEVELOPMENT OF CANINE IMMUNOTHERAPY TARGETED AGENTS

$6.6M

Sep 15, 2026

75N91021F00018

INFRASTRUCTURE IMPROVEMENTS

$4.6M

Sep 24, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N91018F00077?

75N91018F00077 (Cell-based immunotherapy products) is a Nih Nci award with a potential value of $53.5M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91018F00077?

Nih Nci awarded 75N91018F00077 to Leidos Biomedical Research, Inc (potential $53.5M).

Who is the incumbent on 75N91018F00077?

Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Aug 29, 2029.

When does Leidos Biomedical Research, Inc’s 75N91018F00077 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 29, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Aug 22, 2025